Literature DB >> 9070130

Incontinence in elderly women: is periurethral collagen an advance?

S L Stanton1, A K Monga.   

Abstract

OBJECTIVE: To determine whether periurethral collagen is an effective, safe and practical day-case procedure to control genuine stress incontinence (urethral sphincter incompetence) in the elderly female.
DESIGN: Prospective longitudinal study using subjective and objective outcome measures with long term follow up.
SETTING: A teaching hospital tertiary referral centre. SAMPLE: Thirty-two women over 65 years of age with a urodynamic diagnosis of genuine stress incontinence.
RESULTS: At one year, 22 women (79%) were subjectively cured or improved, and 14 (50%) were objectively cured; at two years, 18 (69%) and 14 (54%), respectively. Symptoms of urgency, urge incontinence, frequency and nocturia improved, while voiding difficulty remained unchanged. Brief urinary retention was encountered in seven women. No long term side effects or complications were encountered. Urodynamic studies suggest that collagen works by preventing premature bladder neck opening through physical stress, rather than by obstruction. This would account for the slight increase in functional urethral length.
CONCLUSIONS: Contigen collagen is a simple and effective day case procedure as an alternative to major surgery and is without significant morbidity or complication. It is ideal for the elderly.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9070130     DOI: 10.1111/j.1471-0528.1997.tb11036.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  2 in total

1.  Factors influencing the long-term success of periurethral collagen therapy in the office.

Authors:  Sumana Koduri; Roger P Goldberg; Christina Kwon; Deborah G Dobrez; Peter K Sand
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-10-14

Review 2.  Injectable agents: present and future.

Authors:  Deborah J Lightner; Nancy B Itano; Susan D Sweat; Kristin L Chrouser; Felecia Fick
Journal:  Curr Urol Rep       Date:  2002-10       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.